Bruker Corporation — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; comparisons are with Q1 2021 unless otherwise noted. Bruker develops and sells scientific instruments and analytical and diagnostic solutions through BSI Life Science, BSI Nano and BEST. Figures below are in millions of U.S. dollars, except per-share data and percentages.
Financial performance and liquidity
- Revenue: $595.0, up 7.3% from $554.7. Product revenue was $490.4 and service revenue $103.2. Management reported organic revenue growth of $58.2; unfavorable foreign exchange reduced revenue by approximately $23.7, while acquisitions added $5.8.
- Profit and margins: Gross profit was $306.3, with GAAP gross margin of 51.5%, up from 50.2%. Operating income was $96.5, up 8.3%, and operating margin was 16.2% versus 16.1%. Net income attributable to Bruker was $61.6, up 8.6%; diluted EPS was $0.41 versus $0.37. The effective tax rate rose to 33.9% from 32.2%.
- Cash flow: Operating cash flow was $77.8 versus $98.0. Capital expenditures were $19.0, yielding management-defined free cash flow of $58.8 versus $73.3. Cash, cash equivalents and restricted cash declined $252.1 during the quarter to $819.6.
- Balance sheet and liquidity: Cash and cash equivalents were $816.1 and short-term investments $100.0 at March 31, compared with $1,068.2 and $100.0 at year-end. Total debt was $1,216.4, down from $1,334.2; cash plus short-term investments were $916.1. The company had $599.9 available under its revolving credit lines and reported compliance with debt covenants. Management expects existing cash and credit facilities to meet operating and investing needs for at least the next 12 months.
- Working capital: Inventory rose to $739.9 from $710.1. Customer advances were $214.7, up from $197.5; contract liabilities were $467.9, up from $430.8.
Material changes and business drivers
- BSI Life Science revenue increased 2.6% to $361.0, but segment operating income declined to $85.9 from $88.9 and margin fell to 23.8% from 25.3%.
- BSI Nano revenue rose 15.6% to $178.5; operating income increased to $22.3 from $12.3. BEST revenue grew 13.9% to $59.7, with operating income of $6.6 versus $4.1.
- Management attributed growth to strong demand, including industrial research and semiconductor/microelectronics demand, and recovery in life science markets. Revenue growth was partly offset by currency headwinds. Higher volume and favorable mix supported margins, while inflation, supply-chain challenges, freight and logistics costs, and planned commercial spending pressured results.
- Investing cash outflow included $83.8 for acquisitions and $12.0 for a strategic investment. Financing outflow included $105.0 repayment of 2012 notes, $105.6 of share repurchases and $7.5 of dividends. The company repurchased 1.60 million shares; $275.5 remained under its $500 million repurchase authorization.
Outlook, risks and unusual items
- The filing provides no specific full-year revenue, earnings or margin guidance. Management cited strong demand but cautioned that quarterly results can fluctuate and said it could not accurately predict the full effects of COVID-19 and related uncertainties.
- Key risks include component shortages and longer lead times, increased input and labor costs, inflation, COVID-related disruptions and lockdowns in parts of Asia, geopolitical tensions and trade restrictions, foreign-exchange movements, and customer spending delays. Bruker said it had largely suspended Russian operations and recorded $0.7 of Russia-suspension costs in other charges.
- Other charges were $7.5 versus $3.0, including $5.1 of acquisition-related costs, $1.0 of IT transformation costs, $0.7 related to Russia, $0.4 of investigation-related professional fees and $0.3 of restructuring costs. The tax rate increase reflected U.S. legislation limiting R&D deductibility and foreign tax credit benefits, as well as a tax audit settlement. The company also completed a U.S.-Germany tax treaty resolution during the quarter.
- Bruker acquired a 74.15% interest in PreOmics for a stated cash purchase price of $52.1 and completed other acquisitions. Subsequent events included the April acquisition of Optimal, a merger agreement for IonSense and a minority investment in Tofwerk.
- The company is defending a German patent-infringement claim brought by Carl Zeiss Microscopy against subsidiary Luxendo. Bruker said it believes pending matters will not materially affect its financial statements; no material contingency accruals were recorded.
Important facts for investors to verify
- Whether demand, backlog and the disclosed $2,114.9 of remaining performance obligations convert to revenue as expected; the company expects about 74% to be recognized within 12 months.
- Whether inventory growth, supply constraints and inflation affect delivery timing, cash conversion and margins.
- How foreign-exchange and geopolitical developments, including the suspension of Russian operations, affect reported results and regional demand.
- The cash, debt and integration effects of acquisitions, contingent consideration and the continuing share-repurchase program.
- Developments in the Zeiss litigation, government investigations and uncertain tax positions, including $50.9 of gross unrecognized tax benefits at quarter-end.